22nd Century Group, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lawrence D. Firestone
- Full Time Employees
- 32
- Sector
- Consumer Defensive
- Industry
- Tobacco
- Address
- 321 Farmington Road Mocksville NY United States of America 27028
- IPO Date
- Jan 26, 2011
- CIK
- 0001347858
- Website
- xxiicentury.com
- Similar Companies
- Business
- 22nd Century Group, Inc. (Nasdaq: XXII) is an agricultural biotechnology company focused on tobacco harm reduction through reduced nicotine tobacco products and contract manufacturing services for combustible tobacco items. Founded in 1998 and headquartered in Mocksville, North Carolina, the company develops proprietary tobacco plants with 95% less nicotine using patent-protected technologies including genetic engineering, gene-editing, and molecular breeding; its core offerings include VLN reduced nicotine content cigarettes, the only FDA-authorized modified risk tobacco product (MRTP) combustible cigarette designed to help adult smokers reduce cigarette consumption, SPECTRUM research cigarettes for scientific studies with varying nicotine levels, and turnkey contract manufacturing for third-party branded filtered cigars and cigarettes at its 60,000 square-foot facility capable of producing over 45 million cartons annually. The company serves adult smokers seeking harm reduction alternatives, independent researchers including U.S. government agencies, and other tobacco brands, with primary operations in the United States and potential for international expansion. In recent developments, 22nd Century Group launched its 2025 growth strategy in March 2025 emphasizing profitable contract manufacturing and the relaunch of VLN branded and partner products; it signed a five-year expanded license agreement with Smoker Friendly for its first VLN partner brand with new product launches and shipments starting in Q2 2025, entered a $25 million sales agreement with Needham & Company in November 2025 to fund VLN expansion, completed the sale of Needle Rock Farms assets in May 2025 to strengthen its balance sheet, repaid $3.9 million in senior secured debt in September 2025 achieving a debt-free position bolstered by a $9.5 million non-dilutive insurance settlement, and raised $1.68 million via Regulation A offering in August 2024 while amending its credit facility to enhance financial flexibility.
Company News
22nd Century Same Store Unit Sales for Pinnacle VLN® and Pinnacle Pure Surge 161%
22nd Century Group's Reduced-Nicotine Tobacco Platform Positioned to Support France's Nicotine-Reduction Initiative
22nd Century Group Urges Policymakers and FDA to Enact and Implement the Reduced Nicotine Content Standard, Citing Years Without a Final Rule
22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter
22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group Reports Second Quarter 2026 Financial Results
22nd Century Group to Announce Second Quarter 2026 Results on August 13, 2026
22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing
22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes
22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers
22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand
22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand
22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
22nd Century Group, Inc. (XXII) Q1 2026 Earnings Call Prepared Remarks Transcript
22nd Century Group Reports First Quarter 2026 Financial Results
22nd Century Group Reports First Quarter 2026 Financial Results
22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026
22nd Century Group Shares 2026 Vision for VLN® Product Growth and Tobacco Harm Reduction Leadership